Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Fiasp 100 units/mL Penfill solution for injection in cartridge

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Insulin aspart may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Insulin aspart

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Fiasp® is a mealtime insulin with a fast-acting blood sugar lowering effect. Fiasp® is a solution for injection containing insulin aspart and is used to treat diabetes mellitus in adults, adolescents and children aged 1 year and above. Diabetes is a disease where your body does not produce enough insulin to control the level of blood sugar. Treatment with Fiasp® helps to prevent complications from your diabetes. Fiasp® should be injected up to 2 minutes before the start of the meal, with an option to inject up to 20 minutes after starting the meal. This medicine has its maximum effect between 1 and 3 hours after the injection and the effect lasts for 3 to 5 hours. This medicine should normally be used in combination with intermediate-acting or long-acting insulin preparations.

2.

What you need to know before you take it

e Fiasp®

Do not use Fiasp® ► if you are allergic to insulin aspart, or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Talk to your doctor, pharmacist or nurse before using Fiasp®. Be especially aware of the following: • Low blood sugar (hypoglycaemia) – If your blood sugar is too low, follow the guidance for low blood sugar in section 4 'Possible side effects'. Fiasp® starts to lower blood sugar faster compared to other mealtime insulins. If hypoglycaemia occurs, you may experience it earlier after an injection with Fiasp®. • High blood sugar (hyperglycaemia) – If your blood sugar is too high, follow the guidance for high blood sugar in section 4 'Possible side effects'.

1

• •

• • • •

•

Switching from other insulin medicinal products – Your doctor may need to advise you on your insulin dose. If your insulin treatment is being combined with pioglitazone (oral antidiabetic medicine used to treat type 2 diabetes) – Tell your doctor as soon as possible if you get signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling caused by fluid retention (oedema). Eye disorder – Fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disorder such as diabetic retinopathy. Pain due to nerve damage – If your blood sugar level improves very fast, you may get nerve related pain, this is usually temporary. Swelling around your joints – When you first start using your medicine, your body may keep more water than it should. This causes swelling around your ankles and other joints. This is usually only short-lasting. Ensuring you use the right type of insulin – always check the insulin label before each injection to avoid accidental mix-ups between insulin products. Insulin treatment can cause the body to produce antibodies to insulin (substance that act against insulin). However, only very rarely, this will require a change to your insulin dose.

If you have poor eyesight, please see section 3 'How to use Fiasp®'. Some conditions and activities can affect how much insulin you need. Talk to your doctor: • if you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands. • if you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level. • if you are ill, carry on taking your insulin and talk to your doctor. • If you are going abroad, travelling over time zones may affect your insulin needs and the timing of your injections. When using Fiasp® it is strongly recommended that the name and batch number of each package is recorded in order to maintain a record of the batches used. Skin changes at the injection site The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3 'How to use Fiasp®'). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose. Children and adolescents This medicine is not recommended for use in children below the age of 1 year. Other medicines and Fiasp® Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level – this may mean your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment. Your blood sugar level may fall (hypoglycaemia) if you take: • other medicines for diabetes (oral and injectable) • sulphonamides antibiotics (used to treat infections) • anabolic steroids (such as testosterone) • beta-blockers (used to treat high blood pressure or angina) • salicylates (used to relieve pain and lower fever) • monoamine oxidase inhibitors (MAOI) (used to treat depression)

2

•

angiotensin converting enzyme (ACE) inhibitors (for some heart problems or high blood pressure).

Your blood sugar level may rise (hyperglycaemia) if you take: • danazol (medicine acting on ovulation) • oral contraceptives (birth control pills) • thyroid hormones (for thyroid problems) • growth hormone (for growth hormone deficiency) • glucocorticoids (such as 'cortisone' – for inflammation) • sympathomimetics (such as epinephrine (adrenaline), salbutamol or terbutaline – for asthma) • thiazides (for high blood pressure or if your body is keeping too much water (water retention)). Octreotide and lanreotide – used to treat a rare condition involving too much growth hormone (acromegaly). They may increase or decrease your blood sugar level. If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist. Fiasp® with alcohol If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. You should therefore monitor your blood sugar level more often than usual. Pregnancy and breast-feeding If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. This medicine can be used during pregnancy; however your insulin dose may need to be changed during pregnancy and after delivery. The amount of insulin you need usually falls during the first 3 months of pregnancy and increases for the remaining 6 months. Careful control of your diabetes is needed in pregnancy. Avoiding low blood sugar (hypoglycaemia) is particularly important for the health of your baby. After you have had your baby your insulin requirements will likely return to how much you needed before your pregnancy.

There are no restrictions on treatment with Fiasp® during breast-feeding. Driving and using machines Having low blood sugar can affect your ability to drive or use any tools or machines. If your blood sugar is low, your ability to concentrate or react might be affected. This could be dangerous to yourself or others. Ask your doctor whether you can drive if: ► you often get low blood sugar ► you find it hard to recognise low blood sugar. Important information about some of the ingredients of Fiasp® This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodiumfree'.

3.

How to take it

Fiasp®

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this insulin medicinal product without any help. Get help from a person with good eyesight who is trained to use the pen. When to use Fiasp® Fiasp® is a mealtime insulin.

3

Adults: Fiasp® should be injected right before (0-2 minutes) the start of the meal, with an option to inject up to 20 minutes after starting the meal. Children: Fiasp® should be injected right before (0-2 minutes) the start of the meal, with the possibility to inject up to 20 minutes after starting the meal in situations, when there is uncertainty about how the child will eat. Ask your doctor for advice on these situations. This medicine has its maximum effect between 1 and 3 hours after the injection and the effect lasts for 3 to 5 hours. Fiasp® dose Dose for type 1 and type 2 diabetes Your doctor will decide together with you: • how much Fiasp® you will need at each meal • when to check your blood sugar level and if you need a higher or lower dose. If you want to change your usual diet, check with your doctor, pharmacist or nurse first as a change in diet may alter your need for insulin. When using other medicines, ask your doctor if your treatment needs to be adjusted. Dose adjustment for type 2 diabetes The daily dose should be based on your blood sugar level at mealtimes and bedtime from the previous day. ► Before breakfast – dose should be adjusted according to the blood sugar level before lunch the previous day. ► Before lunch – dose should be adjusted according to the blood sugar level before dinner the previous day. ► Before dinner – dose should be adjusted according to the bedtime blood sugar level the previous day. Table 1 Dose adjustment Mealtime or bedtime blood sugar mmol/L mg/dL less than 4 less than 71 4-6 71-108 more than 6 more than 108

Dose adjustment Reduce dose by 1 unit No dose adjustment Increase dose by 1 unit

Use in elderly patients (65 years or older) This medicine can be used in elderly patients. Talk to your doctor about changes in your dose. If you have kidney or liver problems If you have kidney or liver problems you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose. Injecting Fiasp® This medicine is only suitable for injection under the skin (subcutaneous injection) from a Novo Nordisk reusable insulin pen. Before you use Fiasp® for the first time, your doctor or nurse will show you how to use it. Speak to your doctor if you need to inject your insulin by another method.

Where to inject ► The best places to inject are the front of your waist (abdomen) or upper arms. ► Do not inject into a vein or muscle. ► Change the place within the area where you inject each day to reduce the risk of developing changes under the skin (see section 4).

4

Do not use Fiasp® ► if the cartridge or the reusable pen you are using is damaged. Take it back to your supplier. See your reusable pen manual for further instructions. ► if the cartridge has not been stored correctly (see section 5 'How to store Fiasp®'). ► if the insulin does not appear clear (e.g., cloudy) and colourless. How to inject Fiasp® ► Read the manual that comes with your reusable pen. ► Check the name and strength on the label of the cartridge (Penfill®) to make sure it is Fiasp®. ► Always use a new needle for each injection to prevent contamination. ► Needles must not be shared. If you use more Fiasp® than you should If you use too much insulin your blood sugar may get too low (hypoglycaemia), see advice in section 4 under 'Low blood sugar'. If you forget to use Fiasp® If you forget to use your insulin your blood sugar may get too high (hyperglycaemia). See section 4 under 'High blood sugar'. Three simple steps that may help to avoid low or high blood sugar are: • Always keep spare cartridges of Fiasp®. • Always carry something to show you have diabetes. • Always carry products containing sugar with you. See section 4 under 'What to do if you get low blood sugar'. If you stop using Fiasp® Do not stop using your insulin without talking to your doctor. If you stop using your insulin this could lead to a very high blood sugar level (severe hyperglycaemia) and ketoacidosis (a condition with too much acid in the blood which is potentially life-threatening). See symptoms and advice in section 4 under 'High blood sugar'.

4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Low blood sugar (hypoglycaemia) is very common with insulin treatment (may affect more than 1 in 10 people). It can be very serious. If your blood sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have symptoms of low blood sugar, take actions immediately to increase your blood sugar level. See advice in 'Low blood sugar' below. If you have a serious allergic reaction (including an anaphylactic shock) to insulin or any of the ingredients in Fiasp®, (how often this occurs is not known), stop using this medicine and contact emergency medical service straight away. Signs of a serious allergic reaction may include: • local reactions (e.g., rash, redness and itching) spread to other parts of your body • you suddenly feel unwell with sweating • you start being sick (vomiting) • you experience difficulty in breathing • you experience rapid heartbeat or feeling dizzy. Allergic reactions such as generalised skin rash and facial swelling may occur. These are uncommon and may affect up to 1 in 100 people. See a doctor if the symptoms worsen or you see no improvement in a few weeks. 5

Skin changes at the injection site: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (these are uncommon and may affect up to 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes. Other side effects include: Common (may affect up to 1 in 10 people) Reaction at administration site: Local reactions at the place you inject yourself may occur. The signs may include: rash, redness, inflammation, bruising, irritation, pain and itching. The reactions usually disappear after a few days. Skin reactions: Signs of allergy on the skin such as eczema, rash, itching, hives and dermatitis may occur. General effects from insulin treatment including Fiasp® ►

Low blood sugar (hypoglycaemia) (very common)

Low blood sugar may happen if you: Drink alcohol; use too much insulin; exercise more than usual; eat too little or miss a meal. Warning signs of low blood sugar – these may come on suddenly: Headache; slurred speech; fast heartbeat; cold sweat; cool pale skin; feeling sick; feeling very hungry; tremor or feeling nervous or worried; feeling unusually tired, weak and sleepy; feeling confused; difficulty in concentrating; short-lasting changes in your sight. What to do if you get low blood sugar ► If you are conscious, treat your low blood sugar immediately with 15-20 g of fast-acting carbohydrate: eat glucose tablets or another high sugar snack, like fruit juice, sweets or biscuits (always carry glucose tablets or a high sugar snack, just in case). ► It is recommended that you retest your blood glucose levels after 15-20 minutes and re-treat if your blood glucose levels are still less than 4 mmol/L. ► Wait until the signs of low blood sugar have gone or when your blood sugar level has settled. Then carry on with your insulin treatment as usual. What others need to do if you pass out Tell everyone you spend time with that you have diabetes. Tell them what could happen if your blood sugar gets too low, including the risk of passing out. Let them know that if you pass out, they must: ► turn you on your side to avoid choking ► get medical help straight away ► not give you any food or drink because you may choke. You may recover more quickly from passing out with an injection of glucagon. This can only be given by someone who knows how to use it. • If you are given glucagon you will need sugar or a sugary snack as soon as you come round. • If you do not respond to a glucagon injection, you will have to be treated in a hospital. If severe low blood sugar is not treated over time, it can cause brain damage. This can be short or long-lasting. It may even cause death. Talk to your doctor if: ► your blood sugar got so low that you passed out 6

► you have been given an injection of glucagon ► you have had too low blood sugar a few times recently. This is because the dosing or timing of your insulin injections, food or exercise may need to be changed. ► High blood sugar (hyperglycaemia) High blood sugar may happen if you: Eat more or exercise less than usual; drink alcohol; get an infection or a fever; have not used enough insulin; keep using less insulin than you need; forget to use your insulin or stop using insulin. Warning signs of high blood sugar – these normally appear gradually: Flushed skin; dry skin; feeling sleepy or tired; dry mouth; fruity (acetone) breath; urinating more often; feeling thirsty; losing your appetite; feeling or being sick (nausea or vomiting). These may be signs of a very serious condition called ketoacidosis. This is a build-up of acid in the blood because the body is breaking down fat instead of sugar. If not treated, this could lead to diabetic coma and eventually death. What to do if you get high blood sugar ► Test your blood sugar level. ► Give a correction dose of insulin if you have been taught how to do this. ► Test your urine for ketones. ► If you have ketones, seek medical help straight away. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Great Britain: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store By reporting side effects you can help provide more information on the safety of this medicine.

5.

How to store it

Fiasp®

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and carton, after 'EXP'. The expiry date refers to the last day of that month. Before first use Store in a refrigerator (2°C-8°C). Do not freeze. Keep away from the freezing element. Keep the cartridge in the carton in order to protect from light. After first opening or if carried as a spare Do not refrigerate. You can carry your cartridge (Penfill®) with you and keep it at room temperature (not above 30°C) for up to 4 weeks. Always keep the cartridge in the carton in order to protect from light. Throw away the needle after each injection. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6.

Contents of the pack and other information

7

What Fiasp® contains • The active substance is insulin aspart. 1 mL solution contains 100 units of insulin aspart. Each cartridge contains 300 units of insulin aspart in 3 mL solution. • The other ingredients are phenol, metacresol, glycerol, zinc acetate, disodium phosphate dihydrate, arginine hydrochloride, nicotinamide (vitamin B3), hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment) (see end of section 2 under 'Important information about some of the ingredients of Fiasp®') and water for injections. What Fiasp® looks like and contents of the pack Fiasp® is presented as a clear, colourless and aqueous solution for injection in cartridge. Pack sizes of 5 and 10 cartridges of 3 mL. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark This leaflet was last revised in 08/2022 Fiasp® and Penfill® are trademarks owned by Novo Nordisk A/S, Denmark © 2022 Novo Nordisk A/S

8

Frequently asked questions about Fiasp 100 units/mL Penfill solution for injection in cartridge

How do I take Fiasp 100 units/mL Penfill solution for injection in cartridge?

Fiasp 100 units/mL Penfill solution for injection in cartridge comes as injection containing 100iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Fiasp 100 units/mL Penfill solution for injection in cartridge?

The active substance in Fiasp 100 units/mL Penfill solution for injection in cartridge is insulin aspart.

Are there equivalent medicines to Fiasp 100 units/mL Penfill solution for injection in cartridge?

Medicines with the same active substance, strength and form include: Fiasp 100 units/mL solution for injection in vial, Trurapi 100 units/ml solution for injection in cartridge, Trurapi 100 units/ml solution for injection in pre-filled pen. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Fiasp 100 units/mL Penfill solution for injection in cartridge, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Fiasp 100 units/mL Penfill solution for injection in cartridge without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Insulin aspart (12 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

4.2. Posology and method of administration

Posology

Fiasp is a mealtime insulin for subcutaneous administration up to 2 minutes before the start of the meal, with the option to administer up to 20 minutes after starting the meal (see section 5.1).

Dosing with Fiasp is individual and determined in accordance with the needs of the patient. Fiasp given by subcutaneous injection should be used in combination with intermediate-acting or long-acting insulin given at least once a day. In a basal-bolus treatment regimen approximately 50% of this requirement may be provided by Fiasp and the remaining by intermediate-acting or long-acting insulin.

The individual total daily insulin requirement in adults, adolescents and children may vary and is usually between 0.5 and 1 unit/kg/day.

Blood glucose monitoring and insulin dose adjustment are recommended to achieve optimal glycaemic control.

Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness. Blood glucose levels should be monitored adequately under these conditions.

The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.

Patients on basal-bolus treatment who forget a mealtime dose are advised to monitor their blood glucose level to decide if an insulin dose is needed. Patients should resume their usual dosing schedule at the next meal.

The potency of insulin analogues, including Fiasp, is expressed in units. One (1) unit of Fiasp corresponds to 1 international unit of human insulin or 1 unit of other fast-acting insulin analogues.

The early onset of action must be considered when prescribing Fiasp (see section 5.1).

Initiation

Patients with type 1 diabetes mellitus

The recommended starting dose in insulin naïve patients with type 1 diabetes is approximately 50% of the total daily insulin dose and should be divided between the meals based on the size and composition of the meals. The remainder of the total daily insulin dose should be administered as intermediate-acting or long-acting insulin. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin naïve patients with type 1 diabetes.

Patients with type 2 diabetes mellitus

Suggested initial dose is 4 units at one or more meals. Number of injections and subsequent titration will depend on the individual glycaemic target and the size and composition of the meals.

Dose adjustment may be considered daily based on self-measured plasma glucose (SMPG) on the previous day(s) according to Table 1.

• Pre-breakfast dose should be adjusted according to the pre-lunch SMPG the previous day

• Pre-lunch dose should be adjusted according to the pre-dinner SMPG the previous day

• Pre-dinner dose should be adjusted according to the bedtime SMPG the previous day

Table 1 Dose adjustment

SMPG (see above)

Dose adjustment

mmol/L

mg/dL

Unit

<4

<71

-1

4–6

71–108

No adjustment

>6

>108

+1

Special populations

Elderly patients (≥ 65 years old)

The safety and efficacy of Fiasp have been established in elderly patients aged 65 to 75 years. Close glucose monitoring is recommended and the insulin dose should be adjusted on an individual basis (see section 5.1 and 5.2). The therapeutic experience in patients ≥ 75 years of age is limited.

Renal impairment

Renal impairment may reduce the patient's insulin requirements. In patients with renal impairment, glucose monitoring should be intensified and the dose adjusted on an individual basis (see section 5.2).

Hepatic impairment

Hepatic impairment may reduce the patient's insulin requirements. In patients with hepatic impairment, glucose monitoring should be intensified and the dose adjusted on an individual basis (see section 5.2).

Paediatric population

Fiasp can be used in adolescents and children from the age of 1 year (see section 5.1). There is no clinical experience with the use of Fiasp in children below the age of 2 years.

Fiasp is recommended to be administered prior to the meal (0-2 minutes), with the flexibility to administer up to 20 minutes after starting the meal in situations, when there is uncertainty about the meal intake.

Transfer from other insulin medicinal products

Close glucose monitoring is recommended during the transfer from other mealtime insulins and in the initial weeks thereafter. Converting from another mealtime insulin can be done on a unit-to-unit basis. Transferring a patient from another type, brand or manufacturer of insulin to Fiasp must be done under strict medical supervision and may result in the need for a change in dose.

Doses and timing of concurrent intermediate-acting or long-acting insulin medicinal products or other concomitant antidiabetic treatment may need to be adjusted.

Method of administration

Subcutaneous injection

Fiasp is recommended to be administered subcutaneously by injection in the abdominal wall or the upper arm (see section 5.2). Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8).

Fiasp 100 units/mL Penfill solution for injection in cartridge

Administration with a reusable insulin pen

If administration by syringe or intravenous injection is necessary, a vial should be used. If administration by infusion pump is necessary, a vial or a PumpCart cartridge should be used (see section 6.6).

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypoglycaemia

Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia.

Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement (see sections 4.8 and 4.9).

Patients, whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly. Usual warning symptoms may disappear in patients with long-standing diabetes.

The timing of hypoglycaemia usually reflects the time-action profile of the administered insulin formulation. Hypoglycaemia may occur earlier after an injection/infusion when compared to other mealtime insulins due to the earlier onset of action of Fiasp (see section 5.1).

Since Fiasp should be administered up to 2 minutes before the start of the meal with the option to administer up to 20 minutes after starting the meal, the time to onset of action must be taken into account when prescribing to patients with concomitant diseases or treatment where a delayed absorption of food might be expected.

Paediatric population

Close monitoring of blood glucose levels is recommended if administering this medicinal product after the start of the last meal of the day, in order to avoid nocturnal hypoglycaemia.

Hyperglycaemia and diabetic ketoacidosis

The use of inadequate doses or discontinuation of treatment, especially in patients requiring insulin, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.

Continuous subcutaneous insulin infusion (CSII)

Pump or infusion set malfunctions can lead to a fast onset of hyperglycaemia and ketosis. Prompt identification and correction of the cause of hyperglycaemia or ketosis is necessary. Interim therapy with subcutaneous injection may be required.

Skin and subcutaneous tissue disorders

Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site from an affected to an unaffected area, and dose adjustment of antidiabetic medicinal products may be considered.

Transfer from other insulin medicinal products

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type, origin (animal, human insulin or human insulin analogue) and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dose. Patients transferred to Fiasp from another type of insulin may require a change in dose from that used with their usual insulin medicinal products.

Concomitant illness

Concomitant illness, especially infections and feverish conditions, usually increases the patient's insulin requirements. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland may require changes in the insulin dose.

Combination of pioglitazone and insulin medicinal products

Cases of congestive heart failure have been reported when pioglitazone were used in combination with insulin, especially in patients with risk factors for development of congestive heart failure. This should be kept in mind if treatment with the combination of pioglitazone and insulin medicinal products is considered. If the combination is used, patients should be observed for signs and symptoms of congestive heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.

Insulin initiation and glucose control intensification

Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, acute painful peripheral neuropathy and peripheral oedema. However, long-term glycaemic control decreases the risk of diabetic retinopathy and neuropathy.

Insulin antibodies

Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.

Avoidance of accidental mix-ups/medication errors

Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between this medicinal product and other insulin medicinal products.

Patients must visually verify the units of the dose prior to administering. Therefore, the requirement for patients to self-administer is that they can read the dose scale. Patients, who are blind or have poor vision, must be instructed to always get assistance from another person who has good vision and is trained in administration of insulins.

Travelling between time zones

Before travelling between different time zones, the patient should seek the doctor's advice.

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

A number of medicinal products are known to interact with the glucose metabolism.

The following substances may reduce insulin requirement:

Oral antidiabetics, monoamine oxidase inhibitors (MAOIs), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids, sulphonamides and GLP-1 receptor agonist.

The following substances may increase insulin requirement:

Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.

Beta-blocking agents may mask the symptoms of hypoglycaemia.

Octreotide/lanreotide may either increase or decrease the insulin requirement.

Alcohol may intensify or reduce the hypoglycaemic effect of insulin.

4.6. Fertility, pregnancy and lactation

Pregnancy

Fiasp can be used in pregnancy.

Data from two randomised controlled clinical trials conducted with insulin aspart (322 + 27 exposed pregnancies) do not indicate any adverse effect of insulin aspart on pregnancy or on the health of the foetus/new born when compared to soluble human insulin.

Intensified blood glucose control and monitoring of pregnant women with diabetes (type 1 diabetes, type 2 diabetes or gestational diabetes) are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimesters. After delivery, insulin requirements normally return rapidly to pre-pregnancy values.

Breast-feeding

There are no restrictions on treatment with Fiasp during breast-feeding. Insulin treatment of the breast-feeding mother presents no risk to the baby. However, the dose may need to be adjusted.

Fertility

Animal reproduction studies have not revealed any differences between insulin aspart and human insulin regarding fertility.

4.7. Effects on ability to drive and use machines

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g., driving a car or using machines).

Patients should be advised to take precautions to avoid hypoglycaemia while driving. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.

4.8. Undesirable effects

Summary of safety profile

The most frequently reported adverse reaction during treatment is hypoglycaemia (see section 'Description of selected adverse reactions' below).

Tabulated list of adverse reactions

Adverse reactions listed below (Table 2) are based on data from 6 completed therapeutic confirmatory trials in adults. Frequency categories are defined according to the following convention: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from the available data).

Table 2 Adverse reactions from clinical trials

MedDRA system organ class

Very common

Common

Uncommon

Not known

Immune system disorders

Hypersensitivity

Anaphylactic reactions

Metabolism and nutrition disorders

Hypoglycaemia

Skin and subcutaneous tissue disorders

Allergic skin manifestations

Lipodystrophy

Cutaneous amyloidosis†

General disorders and administration site conditions

Injection/infusion site reactions

† ADR from postmarketing sources.

Description of selected adverse reactions

Allergic reactions

Allergic skin manifestations reported with Fiasp (1.8% vs. 1.5% for comparator) include eczema, rash, rash pruritic, urticaria and dermatitis.

With Fiasp generalised hypersensitivity reactions (manifested by generalised skin rash and facial oedema) was reported uncommonly (0.2% vs. 0.3% for comparator).

Hypoglycaemia

Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation (see sections 4.4 and 5.1). Hypoglycaemia may occur earlier after an injection/infusion of Fiasp compared to other mealtime insulins due to the earlier onset of action.

Skin and subcutaneous tissue disorders

Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Lipodystrophy was reported at the injection/infusion site in patients treated with Fiasp (0.5% vs. 0.2% in comparator). Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).

Injection/infusion site reactions

Injection site reactions (including rash, redness, inflammation, pain and bruising) were reported in patients treated with Fiasp (1.3% vs. 1.0% in comparator). In patients using CSII (N=261): Infusion site reactions (including redness, inflammation, irritation, pain, bruising and itching) were reported in patients treated with Fiasp (10.0% vs. 8.3% in comparator). These reactions are usually mild and transitory and they normally disappear during continued treatment.

Paediatric population

Safety and efficacy have been investigated in a therapeutic confirmatory trial in children with type 1 diabetes aged 2 to less than 18 years. In the trial, 519 patients were treated with Fiasp. Overall the frequency, type and severity of adverse reactions in the paediatric population do not indicate differences to the experience in the adult population. Lipodystrophy (including lipohypertrophy, lipoatrophy) at the injection site was reported more often in this trial with paediatric patients compared to trials in adults (see above). In the paediatric population lipodystrophy was reported with a frequency of 2.1% for Fiasp vs. 1.6% for NovoRapid.

Other special populations

Based on results from clinical trials with insulin aspart in general, the frequency, type and severity of adverse reactions observed in elderly patients and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population. The safety profile in very elderly patients (≥ 75 years) or patients with moderate to severe renal impairment or hepatic impairment is limited. Fiasp has been administered to elderly patients for the investigation of pharmacokinetic properties (see section 5.2).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via

United Kingdom

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if a patient is dosed with more insulin than required:

• Mild hypoglycaemic episodes can be treated by oral administration of glucose or other products containing sugar. It is therefore recommended that the diabetic patient always carries glucose-containing products.

• Severe hypoglycaemic episodes, where the patient is not able to treat him/herself, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional. Glucose must be given intravenously if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness, administration of oral carbohydrate is recommended for the patient in order to prevent a relapse.

💬 Ask about this leaflet

Ask anything about Fiasp 100 units/mL Penfill solution for injection in cartridge. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →